GT Biopharma, Inc. 8-K — AI Bull & Bear Analysis

GT Biopharma has secured a temporary reprieve from Nasdaq, extending its deadline to regain compliance with the minimum bid price requirement until November 16, 2026. While the extension removes the immediate risk of a ticker change or move to the OTC markets, it places the company in a precarious position where it must generate a significant positive catalyst to drive the share price above $1.00 for ten consecutive business days. The outcome now depends on whether the company can deliver clinical or corporate milestones that outweigh the structural risks of its current valuation.